Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,886.80
(
-0.53%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
101.34
(
3.09%
)
Bitcoin
74,390.13
(
-0.61%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: alertmeipp post# 99355

Friday, 07/23/2010 11:29:40 AM

Friday, July 23, 2010 11:29:40 AM

Post# of 257250
As I've posted on numerous occasions, Copaxone is a very much easier drug to characterize than Lovenox. If the FDA was willing to approve MNTA's generic Lovenox, MNTA's obtaining approval for generic Copaxone in due course is close to a fait accompli, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now